News | August 13, 2021
Aurobindo Pharma buys Cronus Pharma Specialities for Rs 420 crores
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
The company is eligible for 12 months exclusivity from launch
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Board approves fundraise of Rs 1500 crore
Turnover of API division of ISLL stood at Rs 856.58 crore
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Subscribe To Our Newsletter & Stay Updated
